Vision Point Advisory Group, LLC Gilead Sciences, Inc. Transaction History
Vision Point Advisory Group, LLC
- $485 Million
- Q4 2025
A detailed history of Vision Point Advisory Group, LLC transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Vision Point Advisory Group, LLC holds 6,527 shares of GILD stock, worth $809,935. This represents 0.17% of its overall portfolio holdings.
Number of Shares
6,527
Previous 4,855
34.44%
Holding current value
$809,935
Previous $538,000
50.37%
% of portfolio
0.17%
Previous 0.11%
Shares
4 transactions
Others Institutions Holding GILD
# of Institutions
2,386Shares Held
1.01BCall Options Held
8.58MPut Options Held
7.35M-
Black Rock Inc. New York, NY121MShares$15 Billion0.19% of portfolio
-
Vanguard Group Inc Valley Forge, PA119MShares$14.8 Billion0.21% of portfolio
-
State Street Corp Boston, MA59.1MShares$7.33 Billion0.23% of portfolio
-
Capital World Investors Los Angeles, CA45.2MShares$5.61 Billion0.72% of portfolio
-
Dodge & Cox San Francisco, CA30.1MShares$3.74 Billion1.93% of portfolio
About GILEAD SCIENCES, INC.
- Ticker GILD
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 1,253,369,984
- Market Cap $156B
- Description
- Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...